Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.


HHS - 15124 - CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment - Authorized by Law
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameCDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and TreatmentAgency NameDepartment of Health and Human Services
Fiscal Year2020Committee Number15124
Original Establishment Date11/22/2002Committee StatusChartered
Actual Termination Date Committee URLhttp://www.cdc.gov/maso/facm/facmchachspt.html
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*Unlimited
Current Charter Date11/25/2020Designated Fed Officer Position Title*DFO
Date Of Renewal Charter11/25/2022Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Jonathan
Exempt From Renewal*NoDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*Mermin
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixMD, MPH
Specific Establishment Authority*42 U.S.C. 217aDesignated Federal Officer Phone*(404) 639-8000
Effective Date Of Authority*11/17/1962Designated Federal Officer Fax*404-639-8600
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*jhm7@cdc.gov
Committee Type*Continuing
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Centers for Disease Control and Prevention (CDC) and Health Resources and Services Administration (HRSA) Advisory Committee on HIV, Viral Hepatitis and Sexually Transmitted Diseases (STD) Prevention and Treatment (CHACHSPT) accomplishes its purpose by deliberating and making recommendations to the U.S. Department of Health and Human Services (HHS) Secretary, the CDC Director, and the HRSA Administrator on timely topics relevant to the Committee’s focus. The Committee establishes workgroups to research and provide reports on issues related to: (1) prevention, control, and treatment of HIV, viral hepatitis, and STDs, and (2) the status of health care services to affected populations. The CHACHSPT accomplishes its purpose through support of CDC and HRSA.
How is membership balanced?*CHACHSPT’s membership is composed of recognized experts with diverse points of view in the field of HIV, Viral Hepatitis and Sexually Transmitted Diseases prevention, treatment, and control. The committee’s members are physicians, academicians, public health administrators, epidemiologists, infectious disease experts, representatives of education and community-based organizations, and people living with HIV. The recruitment process ensures that the membership is balanced by geographic region, race/ethnicity, gender, and expertise.
How frequent & relevant are cmte mtgs?*CHACHSPT met three times in fiscal year 2020. The CHACHSPT activities included holding its regular meetings to discuss critical and timely issues, establishing workgroups to focus on specific topic areas, and sending recommendations and advice to the HHS Secretary, HRSA Administrator, and CDC Director. The Committee provided direction and guidance on a variety of high priority topics. Topics addressed by the committee include the planning for the Ending the HIV Epidemic Initiative and National HIV Plan and calling upon HHS to prioritize young people in the Ending the HIV Epidemic initiative. Examples of CHACHSPT’s activities and focal areas during the period follow below.

The Committee made recommendations for the future direction of CDC and HRSA programs in preventing, controlling, and treating STDs, HIV, and viral hepatitis via correspondence to the HHS Secretary, HRSA Administrator, and CDC Director. CHACHSPT continued to provide advice in 2020 by deliberating on a resolution calling upon HHS to prioritize young people in the Ending the HIV Epidemic initiative. Discussion regarding this topic took place at its March and July 2020 meetings.

Workgroups established by CHACHSTP conducted meetings during the year to research timely topics. These workgroups help inform CHACHSPT so that it may fully implement its charge to deliberate and provide recommendations according to its charter. New workgroups focused on the Ending the HIV Epidemic Initiative, including the National HIV Plan and community engagement; perinatal infections; and accelerating viral hepatitis elimination in the United States.

CHACHSPT provided advice and recommendations on a number of critical issues which included the publication of two key public health guidance documents -- guidance on quality STD clinical services and on screening for hepatitis C. Examples of accomplishments during fiscal year 2020 are shown below.

In January 2020, CDC published recommendations highlighting the services healthcare settings can offer to provide the highest-quality STD care. CHACHSPT provided advice to the HHS Secretary on these recommendations in correspondence on April 25, 2019, noting the guidelines were “urgently needed” and that adherence to them will help lower STD rates. The correspondence also transmitted the CHACHSTP STD Workgroup’s summary report reviewing the CDC “Recommendations for Providing Quality STD Clinical Services.” On January 3, 2020, “Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020” was published in Morbidity and Mortality Weekly Report (MMWR).

In April 2020, CDC published new recommendations for screening for hepatitis C, which included a CHACHSTP recommendation calling for screening of pregnant women. Under the new guidelines, published in MMWR, hepatitis C screening is recommended for all pregnant women during each pregnancy, except in settings where the prevalence of HCV infection is <0.1%. Hepatitis C is increasingly seen in younger people of childbearing years as a consequence of the opioid epidemic. Rates of HCV infection nearly doubled during 2009–2014 among women with live births.

CHACHSPT submitted correspondence to the CDC Director and HRSA Administrator regarding the CDC’s proposed recency testing pilot program. CHACHSPT requested that CDC provide some additional information to inform their feedback. CDC will provide an update during the November 5-6, 2020 CHACHSPT meeting.

CHACHSPT submitted correspondence to the HHS Secretary to prioritize young people, particularly gay, bisexual and transgender youth and youth of color within the National HIV Plan. CHACHSPT members have brought additional attention and analysis to key areas of CDC and HRSA’s work that they address the public’s health.
Why advice can't be obtained elsewhere?*Every year, millions of Americans are infected with HIV, viral hepatitis, and STDs, and tens of thousands die from their infections. The work of CHACHSPT is important in assisting CDC and HRSA achieve their missions related to these infectious diseases. As a joint CDC and HRSA committee, CHACHSPT plays a critical role ensuring an integrated approach to the prevention, care and treatment of HIV, viral hepatitis, and STDs. This unique composition allows for a unified approach to the national HIV, viral hepatitis, and STD agenda, including providing support for the Administration’s Ending the HIV Epidemic initiative and HRSA and CDC programs.
Why close or partially close meetings?N/A
Recommendation RemarksThere was no apparent cost-savings in comparison to the previous year.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesYes
Outcome Major Policy ChangesYesAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryYesAction OtherNo
Outcome Increased Customer SatisfactionYesAction CommentThe agencies work closely with the Committee Co-Chairs to identify priorities and issues to be addressed at committee meetings. Prior to the meetings, the agencies prepare agendas and provide background materials to Advisory Committee members. As needed, the agencies also support workgroups formed by CHACHSPT members, which include presentation by outside experts, to focus on priority issues under the scope of the Advisory Committee.
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentN/ANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentThere was no apparent cost-savings in comparison to the previous year.Grants Review CommentN/A
Number Of Recommendations*170Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe recommendations in FY 2020 fall under these categories: Concerning Ending the HIV Epidemic: A Plan for America and the needs of young people disproportionately impacted by HIV; and CDC’s proposed HIV recency testing pilot program.Access Agency WebsiteYes
% of Recs Fully Implemented*69.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentFor the life of this committee since 2006, 151 recommendations were either fully or partially implemented. Nineteen recommendations have not been initiated by the agencies.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*20.00%Access PublicationsNo
% of Recs Partially Implemented CommentWe are working with the programs on a routine basis to update partially implemented recommendations.Access OtherNo
Agency Feedback*YesAccess CommentInformation for On line Committee Web Site can be found at SBI website: https://www.cdc.gov/faca/committees/chachspt.html
Agency Feedback Comment*Feedback is provided to the CHACHSPT at Committee meetings: by written and electronic correspondence; and in reports and recommendations, which are published in CDC’s Morbidity and Mortality Weekly Reports.Narrative Description*The Committee supports the missions of the Centers for Disease Control and Prevention (CDC) and the Health Resources and Services Administration (HRSA) by providing recommendations on important issues related to the prevention, control, and treatment of HIV, viral hepatitis and STDs, and the support of health care and treatment services to people with HIV.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$9,750.00Est Payments to Non-Fed Members Next FY*$18,000.00
Payments to Federal Members*$15,065.00Est. Payments to Fed Members Next FY*$18,340.00
Payments to Federal Staff*$340,411.00Estimated Payments to Federal Staff*$280,208.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$11,846.00Est Travel Reimb Non-Fed Members nextFY*$15,920.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$3,552.00Est. Travel Reimb to Fed Staff Next FY*$8,419.00
Travel Reimb. For Consultants*$5,250.00Est Travel Reimb to Consultants Next FY*$4,699.00
Other Costs$22,792.00Est. Other Costs Next FY*$23,020.00
Total Costs$408,666.00Est. Total Next FY*$368,606.00
Federal Staff Support (FTE)*2.37Est. Fed Staff Support Next FY*2.07
Cost RemarksEst Cost Remarks
Hide Section - Interest Areas

Interest Areas

Category
Area
Health
Health Care
Treatment
Medicine
Health and Health Research
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-036647CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment2019
 COM-034861CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment2018
 COM-002025CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment2017
 COM-002418CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment2016
 COM-004035CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment2015
 COM-004490CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment2014
 COM-005882CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment2013
 COM-006932CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment2012
 COM-008388CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment2011
 COM-008768CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment2010
 COM-010338CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment2009
 COM-010966CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment2008
 COM-012271CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment2007
 COM-012495CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment2006
 COM-013774CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment2005
 COM-014441CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment2004
 COM-015988CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment2003